| Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model A Roy, MS Singh, P Upadhyay, S Bhaskar International journal of pharmaceutics 445 (1-2), 171-180, 2013 | 81 | 2013 |
| MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers AL MS Singh, S Tammam, MS Boushehri Pharmacological Research, 2017 | 59 | 2017 |
| Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach A Roy, MS Singh, P Upadhyay, S Bhaskar Molecular pharmaceutics 7 (5), 1778-1788, 2010 | 56 | 2010 |
| RNA nanomedicines: the next generation drugs? MS Singh, D Peer Current opinion in biotechnology 39, 28-34, 2016 | 45 | 2016 |
| Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin MS Singh, A Lamprecht International Journal of Pharmaceutics 478 (2), 745-752, 2015 | 33 | 2015 |
| Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems A Rastogi, K Yadav, A Mishra, MS Singh, S Chaudhary, R Manohar, ... Nanotechnology Reviews 11 (1), 544-574, 2022 | 30 | 2022 |
| Nanocarrier-based immunotherapy in cancer management and research MS Singh, S Bhaskar ImmunoTargets and Therapy, 121-134, 2014 | 30 | 2014 |
| Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer MS Singh, S Ramishetti, D Landesman‐Milo, M Goldsmith, S Chatterjee, ... Small 17 (19), 2100287, 2021 | 26 | 2021 |
| P-glycoprotein inhibition of drug resistant cell lines by nanoparticles MS Singh, A Lamprecht Drug Development and Industrial Pharmacy 42 (2), 325-331, 2016 | 26 | 2016 |
| An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics MS Singh, M Goldsmith, K Thakur, S Chatterjee, D Landesman-Milo, ... Nanoscale 12 (3), 1894-1903, 2020 | 24 | 2020 |
| Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation MS Singh, K Juvale, M Wiese, A Lamprecht European Journal of Pharmaceutical Sciences 77, 1-8, 2015 | 24 | 2015 |
| siRNA delivery: current trends and future perspectives MS Singh, D Peer Therapeutic Delivery 7 (2), 51-53, 2016 | 13 | 2016 |
| Extracellular vesicle-derived DNA vs. cfDNA as a biomarker for the detection of colon cancer K Thakur, MS Singh, S Feldstein-Davydova, V Hannes, D Hershkovitz, ... Genes 12 (8), 1171, 2021 | 9 | 2021 |
| Mechanistic insights into nanoparticle surface-bacterial membrane interactions in overcoming antibiotic resistance SK Modi, S Gaur, M Sengupta, MS Singh Frontiers in Microbiology 14, 1135579, 2023 | 6 | 2023 |
| Advances in animal models and cutting-edge research in alternatives: proceedings of the third international conference on 3Rs research and progress, vishakhapatnam, 2022 NN Naik, B Vadloori, S Poosala, P Srivastava, S Coecke, A Smith, ... Alternatives to Laboratory Animals 51 (4), 263-288, 2023 | 2 | 2023 |
| Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation KL Swetha, KS Maravajjala, SD Li, MS Singh, A Roy Drug Delivery and Translational Research 13 (1), 105-134, 2023 | 1 | 2023 |
| Nanocarrier system for overcoming multidrug resistance in cancer MS Singh Universitäts-und Landesbibliothek Bonn, 2015 | 1 | 2015 |
| Oxygen-generating nanomaterials for chronic wound management N Raina, PA Shiekh, A Kumar, MS Singh, PK Gupta, M Gupta Nanomedicine 18 (11), 2023 | | 2023 |
| CD-147 AND CA-9 ARE OVER-EXPRESSED IN SPHEROIDS OBTAINED FROM SEROUS OVARIAN CANCERS O Elyashiv, M Singh, D Landesman-Milo, D Peer, T Levy INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 27, 1574-1574, 2017 | | 2017 |
Dan PeerProf. of NanoMedicine and Immunology, Tel Aviv UniversityVerified email at post.tau.ac.il
